An interventional study of low-level light therapy in Dry Eye and Dry Eyes Chronic, sponsored by Essilor International. Active, not recruiting at 7 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Essilor International · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 544 studies in Dry Eye Syndromes with a site in United States — 52 open to participants now, 63 under way, 3 of them phase 3. Dry Eye Syndromes · United States.
Among the 544 studies in Dry Eye Syndromes with a site in United States, this one is the 147th largest by planned enrollment of the 473 interventional ones that give a count, is one of 36 that started in 2026, is one of 136 with no phase, reaches primary completion later than 24 of the 62 other live ones, and was the 539th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.
Browse Dry Eye Syndromes studies →52 of the 544 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:
Scott & Christie and Associates, PC · Sites in United States
Ages 18+
Bausch & Lomb Incorporated · Sites in United States
Ages 18+
Alcon Research · Sites in United States
Ages 22+ · Healthy volunteers
Cleveland Eye Clinic · Sites in United States
Ages 50–75
Eye Research Associates, LLC · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
544 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 132 · Phase 3 95 · Phase 4 116
First in 1997; this study’s year is marked. 36 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 144 is above the median of 60 across 1,129 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 60 across the 473 interventional studies, 80 across the 64 observational. Of the 439 that completed or were terminated, 232 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
330 of 544 have an industry lead sponsor. The 10 most frequent:
This study is registered under Essilor International, one of the names counted as EssilorLuxottica. Under that name alone:
Essilor International is the lead sponsor of 39 studies on the registry; 20 are open to participants now.
EssilorLuxottica has 4 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
31 of the studies in Dry Eye Syndromes with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07548632Phase 3OculisA Clinical Study Evaluating Licaminlimab for Dry Eye Disease | 2026-12 |
| NCT07281950Center for Sight Las VegasInvestigator Initiated Trial Using Dry Eye Surveys to Evaluate and Better Understand FDA Approved Acoltremon Treatment for Dry Eye Disease in Real World Treatment Settings (DESERT) | 2026-11-30 |
| NCT07566975Neuro-Ophthalmology of TexasReal-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology Clinic: A 6-Month Prospective Observational Study | 2026-11-30 |
| NCT07768735Alcon ResearchUNITY DX Cornea Study | 2026-12 |
| NCT07928986Cleveland Eye ClinicA Multi Center Evaluation of TearCare on Surgical Measurements Before Cataract Surgery | 2026-12 |
Add all 31 to your calendar (.ics) → With an account.
Among the 544 studies in Dry Eye Syndromes with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate the non-inferiority of the Equinox System with respect to iLux 2020.
Approximately 120 participants are expected to take part in the research trial at a minimum of three (3) and up to five (5) sites across the United States.
The expected duration of the study will be six (6) months, and subject participation will take approximately four (4) weeks, including three (4) visits; pretreatment visit, Treatment Day, two (2) week follow-up and four (4) week follow-up visits.
The investigational therapy in this study is the use of low-level light therapy (LLLT) for the treatment of evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands.
Low-Level Light Therapy (LLLT) is a treatment that uses gentle light to help patient cells work better. The light is applied to the skin using special devices. This light can help repair cells that are damaged and improve the function of healthy cells. It may also warm the natural oils in patient eyelids and could reduce tiny mites that sometimes live near the eyelashes. These effects may support overall eye health and comfort.
Participants will be randomized to receive treatment using the Equinox System (red mask) or iLux 2020 System ("iLux system"). There is a 50% chance participant will receive treatment with the Equinox System (red mask) and 50% chance participant will receive treatment with the iLux 2020 System.
For treatment, participant will be placed in either the prone or supine position. Participant will then wear the red mask for 17 minutes. Special protective eyewear or eye protection is not indicated for this treatment; participant will be instructed to keep eyes closed to ensure full application of the treatment to the upper and lower lids and the periorbital area. Immediately after the treatment is finished, the mask will be removed and the meibomian glands will be manually expressed by a trained and qualified clinician.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: low-level light therapy
Device: low-level light therapy
Equinox mask used to deliver low-level light therapy
Equinox System not-inferiority to iLux® System with the respect of change from baseline to Week 4 in Meibomian Gland Score (MGS)
Mean difference between Equinox System or iLux® System in Meibomian Gland Score (MGS) change from baseline to Week 4.
Time frame: 4 weeks
Equinox System not-inferiority to iLux® System with the respect of change from baseline to Week 4 in Tear Break-Up Time (TBUT)
Mean difference between Equinox System and iLux® System in TBUT changes from baseline to Week 4
Time frame: 4 weeks
Characterize the clinical performance of the Equinox System relative to the iLux® System with respect to patient-reported symptom) improvement (OSDI-12)
Change from baseline to Week 4 in Ocular Surface Disease Index (OSDI-12) total score,
Time frame: week 4
Characterize the clinical performance of the Equinox System relative to the iLux® System with respect to patient-reported symptom) improvement tear meniscus height (TMH)
Mean difference between the Equinox System and iLux® System in TMH score changes from baseline to Week 4.
Time frame: week 4
characterize the clinical performance of the Equinox System relative to the iLux® System with respect to patient-reported symptom) improvement lipid layer thickness (LLT)
Mean difference between Equinox System or iLux® System in LLT score changes from baseline to Week 4
Time frame: week 4
characterize the clinical performance of the Equinox System relative to the iLux® System with respect to patient-reported symptom) improvement ocular redness
Mean difference between Equinox System or iLux® System in Hyperemia score changes from baseline to Week 4
Time frame: week 4
characterize the clinical performance of the Equinox System relative to the iLux® System with respect to patient-reported symptom) improvement corneal integrity
Mean difference between Equinox System or iLux® System in Corneal epithelial defect score changes from baseline to Week 4
Time frame: week 4
characterize the clinical performance of the Equinox System relative to the iLux® System with respect to patient-reported symptom) improvement conjunctival epithelial integrity
Mean difference between Equinox System or iLux® System in Conjunctival epithelial defect score changes from baseline to Week 4
Time frame: week 4
characterize the clinical performance of the Equinox System relative to the iLux® System with respect to patient-reported symptom) improvement pain and discomfort
Mean difference between Equinox System or iLux® Systemin change from baseline to Week 4 in pain and discomfort scores assessed using the 0-10 Numerical Rating Scale (NRS) which may be administered as a self completed survey or verbally.
Time frame: week 4
Safety of the Equinox System with that of the iLux® System through a comprehensive evaluation of device- and procedure related risks on ocular surface findings
Incidence, severity, seriousness, and expectedness of device and procedure related adverse events on ocular area
Time frame: 4 weeks
Safety of the Equinox System with that of the iLux® System through a comprehensive evaluation of device and procedure related risks on retinal safety
Incidence, severity, seriousness, and expectedness of device and procedure related adverse events on retina
Time frame: 4 weeks
Safety of the Equinox System with that of the iLux® System through a comprehensive evaluation of device and procedure related risks on patient comfort
collection of pain score (0-10) pre and post treatment (Zero is equivalent to no pain and 10 the worst possible pain) )
Time frame: 4 weeks
Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.
Of 113 industry-sponsored interventional studies with no phase under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's planned 6 months is below that.
Counting every sponsor, half of 312 studies reached it within 10 months; a quarter within 4 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.